![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) …